| Website | aerovance.com |
| Category | BioTech |
| Employees | |
| Description | respiratory, allergic medicines |
| Total | $118M |
| Series C, 3/07 Clarus Ventures Lehman Brothers Alta Partners Apax Partners NGN Capital Burrill & Company | $60M |
| Debt, 3/08 Comerica Bank SVB Financial Group | $20M |
| Unattributed, 4/09 ProQuest Investments BB Biotech Ventures Alta Partners Apax Partners Burrill & Company Clarus Ventures Lehman Brothers Healthcare Fund NGN Capital | $38M |
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
